Wealth Advisors of Tampa Bay LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,190 shares of the company’s stock after selling 921 shares during the quarter. Johnson & Johnson makes up approximately 3.5% of Wealth Advisors of Tampa Bay LLC’s holdings, making the stock its 5th largest position. Wealth Advisors of Tampa Bay LLC’s holdings in Johnson & Johnson were worth $4,283,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of JNJ. Evolution Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $40,000. Horan Securities Inc. boosted its position in shares of Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after purchasing an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its position in shares of Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 80 shares in the last quarter. FNY Investment Advisers LLC boosted its position in shares of Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after purchasing an additional 428 shares in the last quarter. Finally, CKW Financial Group boosted its position in shares of Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after purchasing an additional 128 shares in the last quarter. 66.85% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently commented on JNJ shares. Goldman Sachs Group started coverage on Johnson & Johnson in a research report on Tuesday, May 28th. They issued a “buy” rating on the stock. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target on the stock in a research report on Wednesday, March 27th. Morgan Stanley boosted their price target on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 17th. Barclays started coverage on Johnson & Johnson in a research report on Friday, June 21st. They issued a “hold” rating and a $140.00 price target on the stock. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $152.00 to $156.00 and gave the stock an “outperform” rating in a research report on Thursday, May 16th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $149.89.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion for the quarter, compared to analysts’ expectations of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.06 EPS. As a group, analysts predict that Johnson & Johnson will post 8.6 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th were given a $0.95 dividend. The ex-dividend date of this dividend was Friday, May 24th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 annualized dividend and a yield of 2.73%. Johnson & Johnson’s dividend payout ratio is 46.45%.
In related news, Director Marillyn A. Hewson bought 3,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now owns 3,000 shares in the company, valued at $419,040. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.23% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is a stock portfolio tracker?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.